N-[(2S)-4-methylsulfanyl-1-oxobutan-2-yl]formamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2S)-4-methylsulfanyl-1-oxobutan-2-yl]formamide
• 化学式: C₆H₁₁NO₂S
• 分子量: 161.22
• InChiKey: SASUHVXKFIKDBX-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• METHIONINE ANALOGS AND METHODS OF USING SAME
  申请人：Bassiri Mansour

  公开号：US20110196014A1

  公开（公告）日：2011-08-11

  Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages.

  提供的是蛋氨酸类似物，可用于抑制蛋白质合成，抑制微生物生长和/或治疗传染病。在某些情况下，这些类似物表现出杀菌、抗菌、抗感染、抗微生物、杀孢子、消毒、抗真菌和/或抗病毒的特性。还提供了治疗方法和制备方法，以及套件和单位剂量。
• Chemiluminescence assay of inflammation
  申请人：EXOXEMIS, INC.

  公开号：EP0430440A1

  公开（公告）日：1991-06-05

  The presence or amount of inflammation of a patient is determined by comparing the extent of opsonin receptor expression on phagocytes of a patient with the maximum opsonin receptor expression inducible on phagocytes of the patient in vitro after stimulation with a receptor expression priming agent. Preferably, the state of inflammation of a patient is determined by contacting a first portion of a phagocyte containing biological sample from the patient with an opsonified oxidative metabolism stimulating agent capable of eliciting metabolic activation and with a chemiluminigenic substrate, contacting a second portion of the biological sample from the patient with an opsonin receptor expression priming agent, an opsonified oxidative metabolism stimulating agent capable of eliciting metabolic activation and a chemiluminigenic substrate, and then comparing the chemiluminescence response of the first and second portions of the sample as a measure of the immune response potential or state of inflammation of the patient. Phagocyte function is additionally quantitatively evaluated by measuring the phagocyte oxygenation capacity of a maximally opsonin receptor primed and stimulated biological sample of a patient, determining the specific oxygenation capacity to a set of controls representing the normal distribution of specific oxygenation capacity established from testing a large population. The phagocyte-specific oxygenation capacity is determined by contacting the sample with an opsonin receptor expression priming agent, an opsonified oxidative metabolism stimulating agent and a chemiluminigenic substrate, measuring the chemiluminescence response of the sample, determining the chemiluminescence response per phagocyte of the sample and comparing the response per phagocyte with that of the normal range of values. Kits and reagents are provided for use in the practice of the disclosed methods.

  患者是否存在炎症或炎症的程度，可通过比较患者吞噬细胞上蛋白溶解素受体的表达程度与患者吞噬细胞在体外受受体表达启动剂刺激后可诱导的最大蛋白溶解素受体表达量来确定。患者的炎症状态最好是通过以下方式确定：将患者含有吞噬细胞的生物样本的第一部分与能够引起代谢活化的蛋白氧化代谢刺激剂和化学发光底物接触，再将患者生物样本的第二部分与蛋白吸附素受体表达启动剂接触、然后比较样本第一部分和第二部分的化学发光反应，以此衡量患者的免疫反应潜力或炎症状态。此外，还可通过测量患者最大程度的蛋白溶素受体引物和刺激生物样本的吞噬细胞氧合能力来定量评估吞噬细胞功能，确定与一组对照组相比的特异性氧合能力，这组对照组代表了通过测试大量人群而确定的特异性氧合能力的正常分布。确定吞噬细胞特异性氧合能力的方法是：将样本与一种鸦片素受体表达引物、一种鸦片氧化代谢刺激物和一种化学发光底物接触，测量样本的化学发光反应，确定样本中每个吞噬细胞的化学发光反应，并将每个吞噬细胞的反应与正常值范围的反应进行比较。提供的试剂盒和试剂可用于所公开方法的实践。
• Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity
  申请人：DSM N.V.

  公开号：EP1013769A1

  公开（公告）日：2000-06-28

  Process for the preparation of a compound with enhanced optical purity wherein a mixture of the enantiomers of a chiral compound of formula 1 wherein: R1 represents an alkyl or an aryl group R2 represents H, an alkyl or an aryl group Y represents an alkyl group, an aryl group, (CH2)nCOOH, (CH2)n-COOR, (CH2)n-CONRR', CH2OH, or C≡N wherein R and R' independently represent H, an alkyl or aryl group, and n represents 0 or 1, is brought into contact with an enzyme having peptide deformylase activity with a bivalent metal ion as a cofactor wherein the metal is chosen from the groups 5-11 of the periodic system, or for the preparation of a formylated compound with enhanced optical purity from a mixture of the enantiomers of the corresponding not formylated chiral compound in the presence of a formylation agent. Preferably the peptide deformylase is chosen from the class EC 3.5.2.27 or EC 3.5.1.31, and contains the sequences of (I) HEXXH, (ii) EGCLS and (iii) GXGXAAXQ. The bivalent metal may be chosen from the group of Fe, Ni, Mn and Co, preferably Ni or Fe.

  一种光学纯度更高的化合物的制备工艺，其中包含式 1 手性化合物的对映体混合物 其中 R1 代表烷基或芳基 R2 代表 H、烷基或芳基 Y 代表烷基、芳基、(CH2)nCOOH、( )n-COOR、( )n-CONRR'、 OH 或 C≡N 其中 R 和 R'独立地代表 H、烷基或芳基，n 代表 0 或 1、或在甲酰化剂存在下，从相应的未甲酰化手性化合物的对映体混合物中制备光学纯度更高的甲酰化化合物。肽变形酶最好选自 EC 3.5.2.27 或 EC 3.5.1.31 类，并且 包含以下序列：(I) HEXXH，(ii) EGCLS 和 (iii)GXGXAAXQ。二价金属可选自铁、镍、锰和钴，最好是镍或铁。
• Novel adjuvant for subunit or component vaccines
  申请人：Connaught Technology Corporation

  公开号：EP1800692A1

  公开（公告）日：2007-06-27

  The present invention relates to immunological adjuvants comprised of the N-formyl methionyl peptide fMLP. fMLP, when used as an adjuvant in accordance with the present invention, provides for an immune response to suboptimal doses of recombinant antigens.

  本发明涉及由 N-甲酰基蛋氨酰肽 fMLP 组成的免疫佐剂。根据本发明，当 fMLP 用作佐剂时，可对次优剂量的重组抗原产生免疫反应。
• Conjugates for immunotherapy of cancer
  申请人：Koltermann, Andre

  公开号：EP2275142A2

  公开（公告）日：2011-01-19

  The invention relates to a synthetic bifunctional non-antibody compound comprising one or more effector moieties and one or more binder moieties, wherein the effector moieties are operably linked to the binder moieties via a linker, the effector moieties are ligands to at least one pathogen pattern recognition receptor (PRR) and the binder moieties bind to a marker of a tumor cell.

  本发明涉及一种合成的双功能非抗体化合物，该化合物由一个或多个效应分子和一个或多个粘合剂分子组成，其中效应分子通过连接体与粘合剂分子可操作地连接，效应分子是至少一种病原体模式识别受体（PRR）的配体，粘合剂分子与肿瘤细胞的标记物结合。